Optimize: Immune Resilience
Getting knocked down less, and recovering faster.
Most credible when it corrects a deficiency. The clearest finding is fewer new autoimmune diseases on 2000 IU/day over five years (VITAL, Hahn 2022, about 22% relative reduction). For respiratory infection the picture is now mixed: an early meta showed a small drop (OR 0.92, Martineau 2017) but the large recent CORONAVIT/UK trial found no benefit in adults who were tested and treated. Empower-first and cheap; test-or-supplement modestly if low, do not expect a shield. Condition scope: autoimmune risk, modest respiratory.
Zinc lozenges started within a day of onset shortened colds about a third (roughly 2 days). Honest counterweight: daily zinc does not prevent colds, and high-dose lozenges cause nausea and taste changes. A short at-onset tool, not a daily preventive. Condition scope: cold duration.
Regular (not at-onset) vitamin C shortens colds modestly (about 8% in adults, 14% in children) and roughly halves cold risk under extreme physical stress (marathoners, soldiers). It does not prevent colds in the general population and megadosing at onset does nothing. Cheap; keep expectations low. Condition scope: cold duration, athletes/extreme cold exposure.
About 44% fewer upper-respiratory-infection days in people who train hard, across five small trials, plus fewer cold symptoms in men. The salivary-IgA rise is a marker, not tied to fewer infections. A situational option for heavy exercisers. Condition scope: URTI in athletes.
A cold-shower finish cut self-reported sickness absence 29%, but the actual number of illness days did not change (Buijze 2016). Read it as an absenteeism/self-perception signal, not proof of a stronger immune system. Condition scope: work absence.
Eased allergic rhinitis symptoms across 21 trials, mostly as a low-certainty add-on. A situational adjunct for hay fever. Condition scope: allergic rhinitis.
Ten days of Wim Hof training blunted the inflammatory response to injected endotoxin in 24 healthy men (Kox 2014). A striking single study, but it is an acute lab challenge in the fit and young, not a clinical infection outcome. Condition scope: acute inflammatory response (experimental).
A low-dose mTOR inhibitor raised older adults' flu-vaccine antibody response about 20% and cut respiratory infections the following year (Mannick 2014/2018). Genuinely interesting, but this is an off-label experimental prescription drug with immunosuppressive risk, not a self-directed lever. Frame as investigational, provider-only. Condition scope: immune aging in older adults.
Quercetin calms allergy and inflammation in the lab. In people it did not cut colds overall; only fit adults 40 and over on 1000 mg had fewer sick days (31%). Narrow, subgroup-level. Condition scope: allergy (lab), URTI in older fit adults.
Turkey tail raised immune-cell counts and NK activity in small trials, and PSK has an oncology-adjunct record in Japan. The immune-resilience claim here is marker-level; no cold/flu outcome. Condition scope: immune markers (adjunct oncology elsewhere).
Cold-prevention trials are few and mostly of American ginseng, with no clear pooled direction. Weak base; watch, do not lead. Condition scope: cold prevention (unclear).
Cost Free · $ · $$ · $$$ Effort Easy · Moderate · Hard Results In Same-day · Weeks · Months
Levers with real evidence for immune resilience. Tiers are the strength of that evidence, not our endorsement. An up arrow raises the goal; a down arrow is a reduce-lever.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.